Bionomics is a productive drug discovery and development engine room focused on new treatments for cancer and serious disorders of the central nervous system (CNS). Through application of its proprietary technology platforms, MultiCore®, Angene® and ionX®, Bionomics has generated multiple drug candidates and targets in the therapeutic areas of Cancer, Anxiety, Multiple Sclerosis and Epilepsy. The company has a strong out-license record in conjunction with its in-house development program which has seen two highly promising drugs enter clinical trials in the past two years.

Background

Bionomics was founded in 1999 by a group of Australia's leading healthcare researchers and initially established technology platforms in the genomics of epilepsy, angiogenesis and breast cancer.

Using its CNS technologies, Bionomics became the first company in the world to develop a genetic test for Severe Myoclonic Epilepsy of Infants, a "catastrophic" form of epilepsy for which standard treatments are inappropriate.

Using its Angene® cancer target discovery platform, Bionomics has identified over 150 human genes implicated in angiogenesis - the growth in blood vessels that feed tumours.

In 2005, the company achieved significant milestones in applying its technology to drug discovery. Through the acquisition of two companies, Neurofit Preclinical Research and Iliad Chemicals, it became the first company in Australia to establish a fully-integrated small molecule drug discovery platform. The company now has proprietary technologies for each step in the drug discovery process: Target Discovery and Validation, Compound Libraries, High Throughput Screening, Medicinal Chemistry and Preclinical Development.

The company has internal small molecule discovery programs operating in the following four areas: Angiogenesis and Vascular Targeting Agents (Cancer); Anxiety/Epilepsy and Multiple Sclerosis (CNS diseases).

Bionomics has commercial partnerships with a number of leading healthcare companies including Merck Serono, GenMab, Athena Diagnostics, LabCorp, Perkin Elmer, and Genetic Technologies Ltd.

Pipeline

The status of Bionomics' drug discovery and development programs is summarised below:

Click on a title to learn more about each program:

BNC105
BNO69
Kv1.3 Blockers for Inflammatory Disorders
BNC210
GABA-A Agonists for Epilepsy

Technology

Bionomics is a fully integrated biotechnology company that has created proprietary technology platforms for each step in the drug discovery and development process. Each of these advanced technologies is a source of competitive advantage offering the company the opportunity to identify and progress unique new pharmaceutical products:
MultiCore®
ionX®
Angene®
Publications
Patent Portfolio

For details about Bionomics' partners please CLICK HERE

For details about Bionomics' clinical trials please CLICK HERE

Dr Peter Jonson BComm(Hons), MA(Hons), PhD, FA
Chairman

Dr Deborah Rathjen BSc (Hons), PhD, MAICD
CEO and Managing Director

Dr Errol De Souza
Non-Executive Director

Mr Trevor Tappenden ACA, FAICD
Non-Executive Director

Mr Christopher Fullerton BECon
Non-Executive Director

Mr Stephen Birrell BBus(Acc)
(Chief Financial Officer and Company Secretary)

Dr Emile Andriambeloson PhD
(Head of Research Neurofit)

Dr Andrew Harvey BSc (Hons) PhD
(Vice President Chemistry)

Dr Gabriel Kremmidiotis BSc (Hons), PhD
(Vice President Discovery Research)

As at 14 September 2009, Bionomics Limited had 277,966,257 shares on issue

20 Largest Shareholders - Quoted Ordinary Shares (30 September 2009)